Literature DB >> 27000769

Emerging therapeutic targets in metastatic progression: A focus on breast cancer.

Zhuo Li1, Yibin Kang2.   

Abstract

Metastasis is the underlying cause of death for the majority of breast cancer patients. Despite significant advances in recent years in basic research and clinical development, therapies that specifically target metastatic breast cancer remain inadequate, and represents the single greatest obstacle to reducing mortality of late-stage breast cancer. Recent efforts have leveraged genomic analysis of breast cancer and molecular dissection of tumor-stromal cross-talk to uncover a number of promising candidates for targeted treatment of metastatic breast cancer. Rational combinations of therapeutic agents targeting tumor-intrinsic properties and microenvironmental components provide a promising strategy to develop precision treatments with higher specificity and less toxicity. In this review, we discuss the emerging therapeutic targets in breast cancer metastasis, from tumor-intrinsic pathways to those that involve the host tissue components, including the immune system.
Copyright © 2016 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Breast cancer; Immunotherapy; Metastasis; Targeted therapy; Tumor microenvironment

Mesh:

Year:  2016        PMID: 27000769      PMCID: PMC4851893          DOI: 10.1016/j.pharmthera.2016.03.003

Source DB:  PubMed          Journal:  Pharmacol Ther        ISSN: 0163-7258            Impact factor:   12.310


  304 in total

1.  Expression and clinical significance of androgen receptor in triple negative breast cancer.

Authors:  Xiang Luo; Yan-Xia Shi; Zhi-Ming Li; Wen-Qi Jiang
Journal:  Chin J Cancer       Date:  2010-06

Review 2.  Buparlisib in breast cancer.

Authors:  Bhawna Sirohi; Sameer Rastogi; Shaheenah Dawood
Journal:  Future Oncol       Date:  2015       Impact factor: 3.404

3.  Cyclophosphamide-Mediated Tumor Priming for Enhanced Delivery and Antitumor Activity of HER2-Targeted Liposomal Doxorubicin (MM-302).

Authors:  Elena Geretti; Shannon Curtis Leonard; Nancy Dumont; Helen Lee; Jinzi Zheng; Raquel De Souza; Daniel F Gaddy; Christopher W Espelin; David A Jaffray; Victor Moyo; Ulrik B Nielsen; Thomas J Wickham; Bart S Hendriks
Journal:  Mol Cancer Ther       Date:  2015-07-10       Impact factor: 6.261

4.  Stromal gene expression predicts clinical outcome in breast cancer.

Authors:  Greg Finak; Nicholas Bertos; Francois Pepin; Svetlana Sadekova; Margarita Souleimanova; Hong Zhao; Haiying Chen; Gulbeyaz Omeroglu; Sarkis Meterissian; Atilla Omeroglu; Michael Hallett; Morag Park
Journal:  Nat Med       Date:  2008-04-27       Impact factor: 53.440

Review 5.  The tumor microenvironment and its role in promoting tumor growth.

Authors:  T L Whiteside
Journal:  Oncogene       Date:  2008-10-06       Impact factor: 9.867

6.  A central role for HER3 in HER2-amplified breast cancer: implications for targeted therapy.

Authors:  Si Tuen Lee-Hoeflich; Lisa Crocker; Evelyn Yao; Thinh Pham; Xander Munroe; Klaus P Hoeflich; Mark X Sliwkowski; Howard M Stern
Journal:  Cancer Res       Date:  2008-07-15       Impact factor: 12.701

Review 7.  Androgen receptor expression and outcomes in early breast cancer: a systematic review and meta-analysis.

Authors:  Francisco E Vera-Badillo; Arnoud J Templeton; Paulo de Gouveia; Ivan Diaz-Padilla; Philippe L Bedard; Mustafa Al-Mubarak; Bostjan Seruga; Ian F Tannock; Alberto Ocana; Eitan Amir
Journal:  J Natl Cancer Inst       Date:  2013-11-22       Impact factor: 13.506

8.  Long-term safety and anti-tumour activity of olaparib monotherapy after combination with carboplatin and paclitaxel in patients with advanced breast, ovarian or fallopian tube cancer.

Authors:  Ruud van der Noll; Serena Marchetti; Neeltje Steeghs; Jos H Beijnen; Marja W J Mergui-Roelvink; Emmy Harms; Harriet Rehorst; Gabe S Sonke; Jan H M Schellens
Journal:  Br J Cancer       Date:  2015-07-16       Impact factor: 7.640

Review 9.  Chronic inflammation and cytokines in the tumor microenvironment.

Authors:  Glauben Landskron; Marjorie De la Fuente; Peti Thuwajit; Chanitra Thuwajit; Marcela A Hermoso
Journal:  J Immunol Res       Date:  2014-05-13       Impact factor: 4.818

10.  Investigational drug MLN0128, a novel TORC1/2 inhibitor, demonstrates potent oral antitumor activity in human breast cancer xenograft models.

Authors:  Yesim Gökmen-Polar; Yi Liu; Rachel A Toroni; Kerry L Sanders; Rutika Mehta; Sunil Badve; Christian Rommel; George W Sledge
Journal:  Breast Cancer Res Treat       Date:  2012-10-21       Impact factor: 4.624

View more
  20 in total

1.  Curcumin inhibits MCF-7 cells by modulating the NF-κB signaling pathway.

Authors:  Jun-Li Liu; Yan-Yan Pan; Ou Chen; Yun Luan; Xia Xue; Jing-Jie Zhao; Ling Liu; Hong-Ying Jia
Journal:  Oncol Lett       Date:  2017-08-31       Impact factor: 2.967

2.  The role of liver-directed surgery in patients with hepatic metastasis from primary breast cancer: a multi-institutional analysis.

Authors:  Georgios A Margonis; Stefan Buettner; Kazunari Sasaki; Yuhree Kim; Francesca Ratti; Nadia Russolillo; Alessandro Ferrero; Nickolas Berger; T Clark Gamblin; George Poultsides; Thuy Tran; Lauren M Postlewait; Shishir Maithel; Alex D Michaels; Todd W Bauer; Hugo Marques; Eduardo Barroso; Luca Aldrighetti; Timothy M Pawlik
Journal:  HPB (Oxford)       Date:  2016-06-29       Impact factor: 3.647

3.  Uncarboxylated osteocalcin promotes proliferation and metastasis of MDA-MB-231 cells through TGF-β/SMAD3 signaling pathway.

Authors:  Jiaojiao Xu; Luyao Ma; Danqing Wang; Jianhong Yang
Journal:  BMC Mol Cell Biol       Date:  2022-04-12

Review 4.  Long non-coding RNAs in anti-cancer drug resistance.

Authors:  Qin-Nan Chen; Chen-Chen Wei; Zhao-Xia Wang; Ming Sun
Journal:  Oncotarget       Date:  2017-01-03

5.  RANTES and IL-6 cooperate in inducing a more aggressive phenotype in breast cancer cells.

Authors:  Marianna Gallo; Daniela Frezzetti; Cristin Roma; Nicoletta Chicchinelli; Antonio Barbieri; Claudio Arra; Giosuè Scognamiglio; Gerardo Botti; Antonella De Luca; Nicola Normanno
Journal:  Oncotarget       Date:  2018-04-03

6.  Overexpression of SYF2 promotes cell proliferation and correlates with poor prognosis in human breast cancer.

Authors:  Feng Shi; Feng-Feng Cai; Lu Cai; Xiao-Yan Lin; Wei Zhang; Qin-Qin Wang; Yu-Jie Zhao; Qi-Chao Ni; Hua Wang; Zhi-Xian He
Journal:  Oncotarget       Date:  2017-05-23

7.  microRNA-124 inhibits bone metastasis of breast cancer by repressing Interleukin-11.

Authors:  Wei-Luo Cai; Wen-Ding Huang; Bo Li; Tian-Rui Chen; Zhen-Xi Li; Cheng-Long Zhao; Heng-Yu Li; Yan-Mei Wu; Wang-Jun Yan; Jian-Ru Xiao
Journal:  Mol Cancer       Date:  2018-01-17       Impact factor: 27.401

8.  Slingshot-1L, a cofilin phosphatase, induces primary breast cancer metastasis.

Authors:  Chen Chen; Yusufu Maimaiti; Shen Zhijun; Liu Zeming; Guo Yawen; Yu Pan; Huang Tao
Journal:  Oncotarget       Date:  2017-08-03

9.  A tumor-myeloid cell axis, mediated via the cytokines IL-1α and TSLP, promotes the progression of breast cancer.

Authors:  Emma L Kuan; Steven F Ziegler
Journal:  Nat Immunol       Date:  2018-03-19       Impact factor: 25.606

10.  Macrophage-cancer hybrid membrane-coated nanoparticles for targeting lung metastasis in breast cancer therapy.

Authors:  Chunai Gong; Xiaoyan Yu; Benming You; Yan Wu; Rong Wang; Lu Han; Yujie Wang; Shen Gao; Yongfang Yuan
Journal:  J Nanobiotechnology       Date:  2020-06-16       Impact factor: 10.435

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.